Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study.
暂无分享,去创建一个
A. Tabarin | E. Baudin | F. Beuschlein | J. Bertherat | M. Fassnacht | M. Schlumberger | P. Caron | A. Faggiano | P. Niccoli | B. Goichot | F. Borson‐Chazot | H. Timmers | A. Gimenez-Roqueplo | M. Mannelli | L. Amar | S. Leboulleux | R. Libé | M. Robledo | M. Currás-Freixes | L. Canu | I. Borget | C. de la Fouchardière | D. Drui | D. Vezzosi | A. van Berkel | N. Valdés | C. Do Cao | T. Deutschbein | B. Calsina | S. Hescot | F. Riccardi | S. Laboureau | C. de la Fouchardiére
[1] E. Letouzé,et al. Germline Mutations in the Mitochondrial 2-Oxoglutarate/Malate Carrier SLC25A11 Gene Confer a Predisposition to Metastatic Paragangliomas. , 2018, Cancer research.
[2] C. Wood,et al. Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma , 2017, Annals of surgery.
[3] W. Young,et al. Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta‐analysis , 2017, Clinical endocrinology.
[4] W. Young,et al. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years , 2017, The Journal of clinical endocrinology and metabolism.
[5] A. Gimenez-Roqueplo,et al. Rethinking pheochromocytomas and paragangliomas from a genomic perspective , 2016, Oncogene.
[6] T. Fojo,et al. CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY. , 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[7] Tae Yong Kim,et al. Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: A single institution experience , 2015, Journal of surgical oncology.
[8] A. Tabarin,et al. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. , 2013, The Journal of clinical endocrinology and metabolism.
[9] S. Roman,et al. Malignant pheochromocytoma and paraganglioma: A population level analysis of long‐term survival over two decades , 2013, Journal of surgical oncology.
[10] M. Urioste,et al. MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma , 2012, Clinical Cancer Research.
[11] P. Dahia,et al. An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary Syndromes , 2012, Hormone and Metabolic Research.
[12] T. Fojo,et al. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Lei Feng,et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. , 2011, The Journal of clinical endocrinology and metabolism.
[14] S. Seghezzi,et al. (131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy. , 2010, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[15] K. Takano,et al. Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy. , 2009, The Journal of clinical endocrinology and metabolism.
[16] S. Steinberg,et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine , 2008, Cancer.
[17] R. V. Valdés Olmos,et al. 131I-MIBG Therapy in metastatic phaeochromocytoma and paraganglioma , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[18] E. Baudin,et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. , 2007, The Journal of clinical endocrinology and metabolism.
[19] A. Grossman,et al. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. , 2007, Endocrine-related cancer.
[20] W. Linehan,et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. , 2006, The Journal of clinical endocrinology and metabolism.
[21] K. Byth,et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. , 2006, The Journal of clinical endocrinology and metabolism.
[22] S. Richard,et al. Genetic testing in pheochromocytoma or functional paraganglioma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Karel Pacak,et al. Phaeochromocytoma , 2005, The Lancet.
[24] C. Eng,et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. , 2004, JAMA.
[25] E. Gelmann,et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. , 1988, Annals of internal medicine.